Show simple item record

dc.contributor.authorRicard Cervera (Ed.)*
dc.date.accessioned2021-02-11T08:16:42Z
dc.date.available2021-02-11T08:16:42Z
dc.date.issued2018*
dc.date.submitted2018-05-18 16:21:48*
dc.identifier26724*
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/40976
dc.description.abstractAntiphospholipid syndrome (APS) is an autoimmune disorder caused by antiphospholipid antibodies. It was characterized by excessive clotting of blood and/or certain complications of pregnancy (premature miscarriages, unexplained fetal death, or premature birth) and the presence of antiphospholipid antibodies (such as anti-cardiolipin antibodies or lupus anticoagulant) in the blood. Fifty percent of people with lupus have APS. The exact pathogenesis of APS is inadequately understood, so no specific treatment is available. This Special Issue of Antibodies focuses on the symptoms, pathogenesis, diagnosis, clinical manifestation, therapy of APS, the new research development of antiphospholipid antibodies, and all the other aspects of APS.*
dc.languageEnglish*
dc.subjectQR1-502*
dc.subject.classificationthema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSG Microbiology (non-medical)en_US
dc.subject.otherantiphospholipid syndrome*
dc.subject.otheranticardiolipin antibody*
dc.subject.otherlupus anticoagulant*
dc.subject.otherantiphospholipid antibodies*
dc.titleAntiphospholipid Antibodies and Syndrome*
dc.typebook
oapen.relation.isPublishedBy46cabcaa-dd94-4bfe-87b4-55023c1b36d0*
oapen.relation.isbn9783038429487*
oapen.relation.isbn9783038429470*
oapen.pagesVIII, 128*
oapen.edition1st*


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/